Skip to main content
TMO logo

TMO · Thermo Fisher Scientific Inc.

Track TMO — free
$691.05 -9.17 (-1.31%)
Market Cap
$259.44B
Shares
370.52M
Volume · Nov 16 211.78K Avg daily vol (3M) 2.13M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$700.22 Open$701.42 Day$689.71–702.03 52W close$438.34–721.63 Avg vol 30d2.3M Short int4.8M · 1.3% of shares · 2.0d Short vol30% Last earningsOct 21, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 30

Up next

Jan 28, 2027 Est · unconfirmed · in 10 wks

Latest documents

2026
Oct 30
Quarterly report 10-Q FY2026 Q3, ended Sep 26
Quarterly report for FY2026 Q3

Thermo Fisher Scientific Inc. reported third-quarter revenue of 12,137 million, up 9%, with 6% organic growth; GAAP operating margin rose to 18.6% from 17.4%, and adjusted diluted EPS increased 15% to 6.68.

Revenue $12.14B ▲ 9.1% Net income $1.72B ▲ 6.5% Diluted EPS $4.64 ▲ 8.7%
Read from the MD&A section
Oct 21
Earnings call
Q3 2026 earnings call

Thermo Fisher Scientific reported third-quarter revenue of $12.14 billion, up 9%, and adjusted EPS of $6.68, up 15%. It raised 2026 revenue guidance to $47.7 billion to $48.2 billion and adjusted EPS guidance to $25.13 to $25.43 per share.

Oct 21
Current report 8-K
Financial results

Thermo Fisher Scientific reported third-quarter revenue grew 9% to $12.14 billion, including 6% organic growth; GAAP diluted EPS rose 9% to $4.64 and adjusted EPS rose 15% to $6.68. Adjusted operating margin was 24.5%.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$47.35B
Trailing 12 months
Net income (TTM)
$7.07B
Trailing 12 months
Revenue growth YoY
+9.1%
Year over year
Operating margin
17.9%
Trailing 12 months
P / E (TTM)
36.9
Trailing earnings · reciprocal yield 2.7%
FCF yield
2.9%
TTM · current market cap
Return on invested capital
8.5%
Trailing 12 months
Net cash
−$35.31B
Latest balance sheet
Dividend yield
0.3%
Trailing 12 months
Shares change YoY
-1.9%
Year over year · fewer shares
Price change (1Y)
+20.7%
Trailing year
Short interest
1.3%
Latest settlement · 2.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 21, 2026
Q3 FY26

TL;DR. Thermo Fisher delivered a strong third quarter, with 6% organic revenue growth, 15% adjusted EPS growth, and adjusted operating margin expansion of 120 basis points, while results exceeded prior guidance. The company raised 2026 revenue, adjusted EPS, organic revenue growth, and free cash flow guidance.

Bullish
  • + Third-quarter revenue and adjusted EPS significantly exceeded prior guidance.
  • + Management raised 2026 revenue and adjusted EPS guidance.
  • + Full-year free cash flow guidance increased to $7 billion-$7.5 billion.
  • + Analytical Instruments adjusted operating income rose 26% and margin expanded 430 basis points.
Bearish
  • − Academic and government revenue remained flat.
  • − Specialty Diagnostics reported revenue declined 6%.
  • − Life Sciences Solutions organic revenue growth was only 1%.
  • − A one-time tariff refund contributed $0.15 to third-quarter adjusted EPS.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +26%
above
Price vs 50-day avg +4%
above
RSI (14) 54
neutral
MACD trend Negative
52-week position 92%
near high
Momentum
relative strength
Very Strong
1-month return +1%
trailing
6-month return +56%
trailing
YTD return +21%
this year
Relative strength +56%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $671 › 200d $555 — 50d above 200d
Institutional flow Accumulating
2,544 of 2,646 funds reported for Sep 30 · net +8.3M sh shares · +269 new
Insider flow Distributing
Net -$9.0M over 90 days · 100% sells
Short interest Falling
1.29% of shares out · ▼ -2.1% MoM · 2.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
2,646 holders — mid 3-yr range
Squeeze score 52
elevated · 0–100
Fundamentals
Strong
Revenue growth +14%
Y/Y
EPS growth +7%
Y/Y
Free cash flow $6.3B
Valuation P/E 36.9
in line
Buyback $5.0B
authorized
Balance sheet $29.5B
net debt
Quant / Vol
risk profile
Moderate
Volatility 30%
annualized · 1-yr
Max drawdown −31%
past year
ATR 3.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 6
Latest guidance · from the Earnings Call filed Jul 23, 2026
Revenue · 2026 full year Raised $47.4B – $48.1B
Apr 23, 2026 $47.3B – $48.1B changed to Jul 23, 2026 $47.4B – $48.1B
prior FY $44.56B midpoint +7.2% Y/Y
Adjusted EPS · 2026 full year Non-GAAP Raised $24.93 – $25.33
Apr 23, 2026 $24.64 – $25.12 changed to Jul 23, 2026 $24.93 – $25.33
Free cash flow · 2026 full year Maintained $6.9B – $7.4B
Apr 23, 2026 $6.9B – $7.4B changed to Jul 23, 2026 $6.9B – $7.4B
Net capital expenditures · 2026 full year Maintained $1.9B – $2.1B
Apr 23, 2026 $1.9B – $2.1B changed to Jul 23, 2026 $1.9B – $2.1B
Share buybacks · 2026 full year $4B
Dividends · 2026 full year $700M
Net interest expense · 2026 full year Maintained $660M
Apr 23, 2026 $660M changed to Jul 23, 2026 $660M
FX revenue tailwind · 2026 full year $200M
Acquisitions revenue contribution · 2026 full year $1.6B
Previous outlook earlier release · from the Earnings Call filed Apr 23, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted income tax rate · full year 2026 11.5%
Guided vs delivered · last 6 settled
Revenue guidance 2025 full-year
guided $44.1B – $44.5B
$44.56B Beat +0.6%
Revenue full-year 2024
guided $42.4B – $43.3B
$42.88B In line
Revenue full year 2023
guided $42.7B
$42.86B Beat +0.4%
Revenue full year 2021
guided $37.1B
$39.21B Beat +5.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+26% Bullish
Price vs 50-day avg
+4% Bullish
RSI (14)
54 Neutral
MACD trend
Negative Bearish
52-week position
92% Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $671 › 200d $555 — 50d above 200d
Institutional flow Accumulating
2,544 of 2,646 funds reported for Sep 30 · net +8.3M sh shares · +269 new
Insider flow Distributing
Net -$9.0M over 90 days · 100% sells
Short interest Falling
1.29% of shares out · ▼ -2.1% MoM · 2.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
2,646 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $438 Now $700 · 92% Range high $722
vs 200-day avg +26% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted operating income (non-GAAP measure) non-GAAP $2.74B three months ended June 27, 2026 filing —
GAAP → non-GAAP reconciliation
GAAP GAAP operating income $2.09B
+$28M Cost of revenues adjustments (a)
+$36M Selling, general and administrative expenses adjustments (b)
+$98M Restructuring and other costs (c)
+$485M Amortization of acquisition-related intangible assets
= Adjusted operating income (non-GAAP measure) $2.74B
Adjusted operating income margin (non-GAAP measure) non-GAAP 22.8% three months ended June 27, 2026 filing —
Adjusted tax rate (non-GAAP measure) non-GAAP 11.6% Three months ended June 27, 2026 filing —
Free cash flow (non-GAAP measure) non-GAAP $1.68B three months ended June 27, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TMO
Thermo Fisher Scientific Inc.
this stock
$259.44B +20.8% +14.5% 36.9 1.3%
DHR
Danaher Corp
$163.94B +1.8% +8.5% 38.1 1.2%
IDXX
Idexx Laboratories Inc
$55.48B +4.1% +10.4% 47.5 3.0%
A
Agilent Technologies, Inc.
$49.04B +27.8% +6.4% 34.2 1.7%
NTRA
Natera, Inc.
$46.27B +39.3% -2.8% — 4.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
2,847
% held
92.9%
Reported
2,544 of 2,646
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,318
View
Short & Settlement
Short Interest Falling
Shares short
4.8M
Days to cover
2.0d
Change
-103.1K sh
View
Short Volume
Short vol %
30%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
33
Value
$22.6K
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
48.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$9.0M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Sell
Member
Dan Newhouse
Amount
$1.0K–$15.0K
Traded
Jul 10, 2026
View
Financials
Financials
Revenue (FY)
$44.6B
Net income (FY)
$6.7B
EPS diluted
$17.74
View
Buybacks
Authorized
$5.0B
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 30, 2026
This year
20

Thermo Fisher Scientific Inc. announced that Executive Vice President Michael D. Shafer will retire effective December 31, 2026.

View
Proposed Sales
Value
$2.9M
Shares
4.1K
Filed
Nov 13, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 19, 2026
Last webcast
Oct 21, 2026
View
Investor Relations
Latest news
Thermo Fisher Scientific to Parti…
Published
Nov 13, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
TMO +0.8% +1.5% +56.2% +0.5% +20.8%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -1.8% +2.6% +55.7% +0.6% +10.2%

Capital returns

Latest dividend
$0.47 / share · ex Sep 15, 2026
Declared · upcoming
$0.47 / share · ex Dec 15, 2026
Raised 9.3%
Paid (TTM)
$1.84 / share · 4 payouts
Dividend yield (TTM, derived)
0.26%
Full dividend history
Buyback program · as of Nov 5, 2026
Authorized
$5.00B
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 97745 CUSIP 883556102 13F (30d) 2141 filings 2035 filers Visit website Investor relations